Where we see income opportunities as the Fed winds down stimulus
We share how we employ a flexible approach to tap into income opportunities.
Demand for health care services and products in China continues to grow, alongside the government’s effort to advance the sector’s development with increased investments in related infrastructure, pharmaceutical research, medical diagnostics as well as preventive treatment.
Admittedly, serious diseases such as cancer and hypertension have been on the rise globally, and China isn’t spared from this trend. For example, cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 20202. China’s cancer registration system covered 598 million people in 2020, an increase of 140 million from 20193.
Our EMAP Equities team shares their views on some of the key trends in China’s health care sector and the growth potential1.
1. While China still lags other major developed markets in terms of medical research and innovation, what are the drivers in China’s health care industry?
Seeking health care opportunities across China
2. Where do we see opportunities in China’s health care industry?
|What are …|
|Pharmaceutical firms generally outsource their research work to CROs to help lower the costs of conducting trials which could include setting up the infrastructure, renting a space or employing the professionals conduct research and tests.||CDMOs entered into contracts with pharmaceutical firms to provide comprehensive drug development and manufacturing services. CDMOs are tasked as pharmaceutical firms may lack the manufacturing facilities or expertise that are needed in pre-clinical and clinical trials.|
Accessing all-encompassing China-focused solutions